, Tracking Stock Market Picks
Enter Symbol:
Rating: STJ
Overweight $86
up 14.00 %

St. Jude Medical, Inc. (NYSE: STJ) reiterated to Overweight with price target $86 by Barclays

Thursday,  Jul 23, 2015  12:25 PM ET by Dave Ficere

Barclays reiterated St. Jude Medical, Inc. (NYSE: STJ) to Overweight with price target $86. Previously Barclays rated Overweight with price target $75 St. Jude Medical,
Inc. (NYSE: STJ) on 01/16/2014, when the stock price was $66.81. Since then, St. Jude Medical, Inc.'s stock price has gained 14% as of 07/23/2015's recent price of $76.01.
If you would have followed the previous Barclays's recommendation on STJ, you would have gained 14% of your investment in 553 days.

St. Jude Medical, Inc. (St. Jude)develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and implantable neurostimulation devices for the management of chronic pain. The Company operates in four business segments: Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation Systems (Neuro). On July 3, 2008, the Company completed the acquisition of EP MedSystems, Inc. On December 19, 2008, St. Jude acquired Radi Medical Systems. On December 22, 2008, St. Jude acquired MediGuide Inc.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy